Lubomir Vezenkov was born in Bulgaria, where he performed his studies until he arrived in Montpellier in 2005 for his masters at the ENSCM engineering school. Then, he performed a co-tutoring PhD thesis between the universities of Montpellier and Naples, which he graduated from in 2011. During this period, he helped develop some potent cell penetrating foldamers that were used to vectorize pepstatin and provide selective anti-cancer activity. Afterwards, Lubomir did a two-years-long postdoctoral internship in the Prof. Robert Young group in Simon Fraser University, Vancouver, where he took part in the development of one of the first specific autophagy inhibitors. Then, he moved back to Montpellier, and in 2016, he received an associate professor position at ENSCM in team 9 of the IBMM research institute. Currently, he is working in the fields of peptide and medicinal chemistry as well as in the exciting domain of chemical biology. Recently he has been interested in the development of covalent-irreversible and covalent-reversible protease inhibitors. These covalent modifiers are used to block or activate certain microtubulin post-translational modifications. Such compounds can help better understand the polarization of neurons and can be used as therapeutics for neurodegenerative disease. https://fr.linkedin.com/in/lubomir-vezenkov-31b1b9208